Scarica l'app Stockscreener
290.19
1.17%
3.36
Dopo l'orario di chiusura:
295.00
4.81
+1.66%
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets - AD HOC NEWS
Charles River Labs Q3 Results: Adj EPS Expected At $2.90$3.00 - scanx.trade
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 - Moomoo
Halper Sadeh investigates Charles River Labs over fiduciary breaches - scanx.trade
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
UBS resumes Charles River Labs stock coverage with buy rating By Investing.com - Investing.com Australia
UBS resumes Charles River Labs stock coverage with buy rating - Investing.com
UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook - GuruFocus
Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization - AD HOC NEWS
Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6 - TradingView
Charles River stock: Company reaffirms 2026 guidance and sets 2030 targets - AD HOC NEWS
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery - Yahoo Finance
Charles River Laboratories International, Inc. Cash Flow – HAN:RV6 - TradingView
Charles River Laboratories stock trades near a yearly high as targets rise - AD HOC NEWS
Charles River Laboratories stock at USD 294.59 on September 28, 2026 - AD HOC NEWS
Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors? - Simply Wall Street
Is Charles River Laboratories Stock Outperforming the S&P 500? - Barchart.com
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating - moomoo.com
Charles River (NYSE:CRL) In Focus As Investor Day Unveils Pathway To Purpose And Lifts Near-Term View - Kalkine Media
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan - Yahoo Finance
Charles River Labs stock sets USD 11.45 EPS outlook after Investor Day - AD HOC NEWS
Charles River Laboratories: Positive Investor Day Is Fully Priced In (NYSE:CRL) - Seeking Alpha
Mizuho raises Charles River Labs stock price target to $295 on outlook - Investing.com
RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating - Yahoo Finance
Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating - marketscreener.com
TD Cowen raises Charles River Labs stock price target on growth outlook - Investing.com Canada
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch - Yahoo Finance
Charles River Labs stock rises 5.2 percent ahead of the open - AD HOC NEWS
Why Charles River Laboratories (CRL) Stock Is Up Today - Yahoo Finance
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories (CRL) Reaffirms 2026 Guidance and Unv - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300 - Bitget
CRL: 2030 targets: 5%-7% sales CAGR, ~24% margins, $300M savings, and digital-driven growth - TradingView
CRL: 2030 targets: 5%-7% sales CAGR, 24% margins, and $300M in savings via AI-driven modernization - TradingView
Charles River Laboratories International Jumps 5.1% in Broad Rally - AlphaStreet
Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement - TradingKey
Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets - Quiver Quantitative
Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View - Simply Wall Street
Charles River stock rises on promising 2026 outlook (CRL:NYSE) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Charles River Laboratories International, Inc. (CRL) Analyst/Investor DaySlideshow (NYSE:CRL) 2026-09-24 - Seeking Alpha
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day - BioSpace
Charles River Laboratories International, Inc. Investor Day 2026 Transcript - gurufocus.com
Over $300M in savings is expected from 2027 to 2030 as Charles River (CRL) sets a revenue growth target. - Stock Titan
Charles River Labs reiterates FY26 outlook, targets 5-7% growth by 2030 - scanx.trade
Charles River Laboratories stock falls 2.73 percent after Q2 results - AD HOC NEWS
Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections - marketscreener.com
CRL: 2030 targets: 5–7% organic revenue CAGR, ~24% margin, and $300M+ in cost savings - TradingView
CRL: Modernization and digitalization drive growth, with 5–7% organic revenue CAGR targeted by 2030 - TradingView
Charles River Laboratories stock trades below its yearly high - AD HOC NEWS
Charles River Labs stock falls 1.4 percent ahead of the open - AD HOC NEWS
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Labs stock rises 2.19 percent ahead of the open - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Charles River Laboratories stock holds near its yearly high - AD HOC NEWS
Charles River Laboratories stock holds near its yearly high on mixed results - AD HOC NEWS
Charles River Labs stock heads into the open after a 1.28 percent drop - AD HOC NEWS
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter - Yahoo Finance
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):